DAMICO JENNIFER B. sold $51K of PFE

Pfizer (PFE) stock has declined 19.19% over five years, resulting in a 6% dividend yield. The company paid $9.77 billion in dividends in 2025, with a thin cash cushion. CEO Albert Bourla assured dividend maintenance but ruled out near-term hikes. Q2 2026 adjusted EPS was $0.77, beating estimates, with full-year guidance of $2.80-$3.00.

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

The FDA approved new COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for 2026-27, targeting current variants. Moderna received approval for two vaccines. Distribution will be limited to specific age groups and high-risk individuals, with availability expected in the fall.

PFE, GTLB, and COP stocks reached 52-week highs. PFE rose 1.65% after FDA approval of its updated COVID-19 vaccine and strong Q2 results. GTLB gained 10% on strong Q2 results and price target hikes. COP climbed 0.74% due to rising oil prices from Middle East tensions.

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.